Literature DB >> 10217148

Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing.

P Davidsson1, M Puchades, K Blennow.   

Abstract

Synaptic pathology is central in the pathogenesis of several psychiatric disorders, for example in Alzheimer's disease (AD) and schizophrenia. Quantification of specific synaptic proteins has proved to be a useful method to estimate synapitc density in the brain. Using this approach, several synaptic proteins have been demonstrated to be altered in both AD and schizophrenia. Until recently, the analysis of synaptic pathology has been limited to postmortem tissue. In living subjects, these synaptic proteins may be studied through analysis of cerebrospinal fluid (CSF). In an earlier study performed by us, one synaptic vesicle specific protein, synaptotagmin, was detected in CSF for the first time using a procedure based on affinity chromatography, reversed-phase chromatography, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and chemiluminescence immunoblotting. However, other synaptic proteins were not detectable with this procedure. Therefore, we have developed a procedure including precipitation of CSF proteins with trichloroacetic acid, followed by liquid-phase isoelectric focusing using the Rotofor Cell, and finally analysis of Rotofor fractions by Western blotting for identification of synaptic proteins in CSF. Five synaptic proteins, rab3a, synaptotagmin, growth-associated protein (GAP-43), synaptosomal-associated protein (SNAP-25) and neurogranin, have been demonstrated in CSF using this method. The major advantage of liquid-phase isoelectric focusing (IEF) using the Rotofor cell is that it provides synaptic proteins from CSF in sufficient quantities for identification. This method may also be suitable for identification of other types of trace amounts of brain-specific proteins in CSF. These results demonstrate that several synaptic proteins can be identified and measured in CSF to study synaptic function and pathology in degenerative disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217148     DOI: 10.1002/(SICI)1522-2683(19990301)20:3<431::AID-ELPS431>3.0.CO;2-2

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  24 in total

1.  Both total and phosphorylated tau are increased in Alzheimer's disease.

Authors:  M Sjögren; P Davidsson; M Tullberg; L Minthon; A Wallin; C Wikkelso; A K Granérus; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

2.  Biomarkers in Alzheimer's disease drug development.

Authors:  Kaj Blennow
Journal:  Nat Med       Date:  2010-09-21       Impact factor: 53.440

3.  Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.

Authors:  Erik Portelius; Henrik Zetterberg; Tobias Skillbäck; Ulrika Törnqvist; Ulf Andreasson; John Q Trojanowski; Michael W Weiner; Leslie M Shaw; Niklas Mattsson; Kaj Blennow
Journal:  Brain       Date:  2015-09-15       Impact factor: 13.501

Review 4.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

Review 5.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

Authors:  Kaj Blennow; Harald Hampel; Michael Weiner; Henrik Zetterberg
Journal:  Nat Rev Neurol       Date:  2010-02-16       Impact factor: 42.937

Review 6.  Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

Authors:  Alberto Lleó; Enrica Cavedo; Lucilla Parnetti; Hugo Vanderstichele; Sanna Kaisa Herukka; Niels Andreasen; Roberta Ghidoni; Piotr Lewczuk; Andreas Jeromin; Bengt Winblad; Magda Tsolaki; Barbara Mroczko; Pieter Jelle Visser; Isabel Santana; Per Svenningsson; Kaj Blennow; Dag Aarsland; José Luis Molinuevo; Henrik Zetterberg; Brit Mollenhauer
Journal:  Nat Rev Neurol       Date:  2014-12-16       Impact factor: 42.937

Review 7.  Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.

Authors:  Simone Lista; Henrik Zetterberg; Bruno Dubois; Kaj Blennow; Harald Hampel
Journal:  J Neurol       Date:  2014-05-08       Impact factor: 4.849

Review 8.  Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?

Authors:  Guillermo Moya-Alvarado; Noga Gershoni-Emek; Eran Perlson; Francisca C Bronfman
Journal:  Mol Cell Proteomics       Date:  2015-12-11       Impact factor: 5.911

Review 9.  Fluid biomarkers in Alzheimer disease.

Authors:  Kaj Blennow; Henrik Zetterberg; Anne M Fagan
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

10.  An overview of biomarkers in Alzheimer's disease.

Authors:  Pandurang R Wattamwar; P S Mathuranath
Journal:  Ann Indian Acad Neurol       Date:  2010-12       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.